Acorda Therapeutics, Inc. (ACOR)
(Delayed Data from NSDQ)
$11.74 USD
+1.16 (10.96%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.74 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.74 USD
+1.16 (10.96%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.74 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Immunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2
by Zacks Equity Research
Immunomedics (IMMU) posts wider-than-expected loss and generates no revenues in the second quarter of 2019.
Horizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates
by Zacks Equity Research
Horizon (HZNP) beats earnings and sales estimates in the second quarter of 2019.
Catalyst's (CPRX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Catalyst (CPRX) surpasses earnings and sales estimates in the second quarter of 2019.
Blueprint Medicines (BPMC) Q2 Loss Widens, Sales Top Mark
by Zacks Equity Research
Blueprint Medicines (BPMC) suffers wider-than-expected loss in the second quarter while sales beat estimates.
Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Acorda (ACOR) posts narrower-than-expected loss while revenues top estimates in the second quarter. Inbrija delivers a solid start with sales rising sequentially.
Emergent (EBS) Earnings Miss in Q2, Revenues Beat Estimates
by Zacks Equity Research
Emergent's (EBS) earnings miss estimates in the second quarter of 2019 while revenues surpass the mark.
Geron (GERN) Stock Up Despite Q2 Earnings & Sales Miss
by Zacks Equity Research
Geron (GERN) posts a wider-than-expected loss in second-quarter 2019. Operating expenses increase on a year-over-year basis.
IVERIC bio's (ISEE) Q2 Loss Narrows, Gene Therapy in Focus
by Zacks Equity Research
IVERIC bio (ISEE) second-quarter earnings improve year over year. The company is focusing on developing gene therapies for treating inherited retinal diseases.
Acorda Therapeutics (ACOR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Acorda (ACOR) delivered earnings and revenue surprises of 48.11% and 91.32%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Agios' (AGIO) Loss Widens in Q2, Tibsovo Drives Sales
by Zacks Equity Research
Agios (AGIO) incurs wider-than-expected loss in Q2 while revenues beat estimates. The company's newly approved leukemia drug Tibsovo sees a rise in sales sequentially.
Vertex (VRTX) Beats on Q2 Earnings, Ups CF Product Sales View
by Zacks Equity Research
Vertex (VRTX) beats on earnings and sales in second-quarter 2019. The company lifts its full-year revenue guidance, led by a solid CF products' performance, especially Symdeko.
Amgen (AMGN) Catches Eye: Stock Jumps 5.7%
by Zacks Equity Research
Amgen (AMGN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Celgene (CELG) Beats on Q2 Earnings, Raises Revenue Guidance
by Zacks Equity Research
Celgene (CELG) beats on earnings and sales in second-quarter 2019. The company raises full-year revenue guidance on solid Pomalyst and Abraxane performances.
Alkermes (ALKS) Earnings and Sales Beat Estimates in Q2
by Zacks Equity Research
Alkermes (ALKS) surpasses earnings and sales estimates in the second quarter of 2019.
Medicines Company (MDCO) Q2 Earnings Top, Inclisiran in View
by Zacks Equity Research
The Medicines Company (MDCO) posts narrower-than-expected loss in Q2. The company did not generate any revenues in the period while its focus is steady on its sole pipeline candidate, inclisiran.
Acorda (ACOR) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Acorda's (ACOR) second-quarter earnings call, investor focus will be on the sales uptick of its newly launched Parkinson's disease drug Inbrija.
Analysts Estimate Acorda Therapeutics (ACOR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acorda Therapeutics (ACOR) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Acorda Therapeutics (ACOR) closed at $6.82, marking a +0.89% move from the previous day.
Alexion (ALXN) Q2 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Alexion (ALXN) beats both earnings and sales estimates in the second quarter of 2019 and raises 2019 guidance.
Horizon's NDA for Procysbi New Dosage Form Accepted by FDA
by Zacks Equity Research
The FDA accepts Horizon Therapeutics' (HZNP) NDA for Procysbi (Cysteamine Bitartrate) delayed-release oral granules in packets.
Exelixis Adds & Expands Cohorts in Cabometyx-Tecentriq Study
by Zacks Equity Research
Exelixis (EXEL) adds four cohorts and expands two cohorts in the early-stage study evaluating lead drug, Cabometyx, in combination with Tecentriq.
FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug
by Zacks Equity Research
The FDA accepts Neurocrine's (NBIX) NDA for opicapone, developed as an adjunctive treatment to levodopa/carbidopa for patients with Parkinson's disease, who currently experience OFF episodes.
Horizon Therapeutics Files BLA to FDA for Eye Disease Drug
by Zacks Equity Research
Horizon Therapeutics (HZNP) files a BLA for teprotumumab to the FDA for the treatment of active thyroid eye disease.
ObsEva Ends Recruitment in Second Uterine Fibroids Study
by Zacks Equity Research
ObsEva (OBSV) completes patient recruitment in the second pivotal phase III study evaluating linzagolix for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids.
Catalyst Pharma Focuses on Firdapse Launch & Label Expansion
by Zacks Equity Research
Catalyst Pharmaceuticals (CPRX) intends to launch Firdapse and expand the label of the same.